Siren L.L.C. Sells 87,738 Shares of Taysha Gene Therapies, Inc. $TSHA

Key Points

• Siren L.L.C. has reduced its holdings in Taysha Gene Therapies by 1.3%, selling 87,738 shares, while maintaining approximately 6.5 million shares valued at $9 million.
• Multiple institutional investors have increased their stakes in Taysha Gene Therapies, with Bank of America Corp DE growing its investment by 1,178.9% in the last quarter.
• Analysts have positively revised their price targets for Taysha Gene Therapies, with estimates ranging from $6.00 to $11.00 and an average consensus target price of $8.29.

Siren L.L.C. decreased its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 1.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,514,737 shares of the company's stock after selling 87,738 shares during the quarter. Siren L.L.C. owned approximately 3.18% of Taysha Gene Therapies worth $9,055,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of TSHA. Bank of America Corp DE grew its stake in shares of Taysha Gene Therapies by 1,178.9% in the fourth quarter. Bank of America Corp DE now owns 1,710,303 shares of the company's stock worth $2,959,000 after purchasing an additional 1,576,568 shares during the last quarter. ADAR1 Capital Management LLC grew its stake in shares of Taysha Gene Therapies by 500.0% in the first quarter. ADAR1 Capital Management LLC now owns 1,066,309 shares of the company's stock worth $1,482,000 after purchasing an additional 888,602 shares during the last quarter. Palo Alto Investors LP lifted its holdings in Taysha Gene Therapies by 75.0% in the first quarter. Palo Alto Investors LP now owns 1,419,468 shares of the company's stock valued at $1,973,000 after buying an additional 608,200 shares during the period. Nuveen LLC acquired a new position in Taysha Gene Therapies in the first quarter valued at $760,000. Finally, Kovitz Investment Group Partners LLC acquired a new position in Taysha Gene Therapies in the first quarter valued at $407,000. Institutional investors own 77.70% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on TSHA. JMP Securities boosted their target price on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a report on Thursday, May 29th. Needham & Company LLC restated a "buy" rating and issued a $8.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, July 1st. Canaccord Genuity Group boosted their target price on shares of Taysha Gene Therapies from $9.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, June 3rd. Chardan Capital boosted their target price on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. Finally, Citigroup restated an "outperform" rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. Eight investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $8.29.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA opened at $3.25 on Thursday. The firm's 50-day moving average price is $2.78 and its 200-day moving average price is $2.29. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $3.40. The firm has a market capitalization of $886.60 million, a P/E ratio of -9.56 and a beta of 0.98. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.17.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. The company had revenue of $1.99 million for the quarter, compared to analyst estimates of $1.61 million. Equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.